November 09, 2023
2 min watch
Save
VIDEO: Vevye shows minimal side effect profile for treating DED symptoms
Issue: January 25, 2024
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, John D. Sheppard, MD, MMSc, discusses the use of Vevye from Harrow to treat dry eye disease.
Vevye, a 0.1% cyclosporine ophthalmic solution, is the first cyclosporine-containing product to receive FDA approval for treating signs and symptoms of DED, as well as the first to demonstrate a minimal side effect profile, Sheppard said.
“You, as the prescriber, will find a successful level of enthusiasm, results, side effect reduction and sign and symptom improvement for your dry eye patients,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Sheppard reports receiving funding from Harrow.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.